The purpose of this study is to determine if patiromer treatment of subjects who developed hyperkalemia while receiving RAASi medications will result in continued use of RAASi medications in accordance with heart failure (HF) treatment guidelines and thereby decrease the occurrence of the combined endpoint of cardiovascular (CV) death and CV hospitalization events compared with placebo treatment.
Investigator: Ellis C. Dillon, Ph.D.
Investigator: Bob S. Hu, M.D.
Culturally Adapted DPP [Diabetes Prevention Program] Intervention for Mexican Americans in Primary Care: An RCT [randomized controlled trial]
Investigator: Kristen M.J. Azar, R.N., BSN, MSN/MPH
Investigator: Jiang Li, Ph.D., MPH